Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Front-line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced RCC

Michael Atkins • 26 May 2020
ASCO 2020
Kidney Cancer

Michael Atkins, MD, Georgetown University, Washington, DC discusses the Phase II study of front line therapy with nivolumab and salvage nivolumab and ipilimumab in patients with advanced renal cell carcinoma (NCT03117309). This video was recorded via an online conference call with the Video Journal of Oncology (VJOncology).

More from Michael Atkins

1:46
Clinical trials in kidney cancer to look out for
Michael Atkins • 17 Feb 2023
1:34
Potential new biomarkers for advanced ccRCC treatment response identified
Michael Atkins • 17 Feb 2023
6:16
Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC
Michael Atkins • 17 Feb 2023
1:44
TIVO-3: tivozanib hydrochloride vs sorafenib for refractory advanced RCC
Michael Atkins • 18 Feb 2022

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:52
LITESPARK-004: ESA use in VHL disease-associated RCC
Benjamin Maughan • 26 Jan 2024
3:04
Evaluating the role of radiotherapy in primary and metastatic RCC
Sophia Kamran • 26 Jan 2024
2:14
Managing renal cell carcinoma after progressing on checkpoint inhibitors
David Braun • 14 Feb 2024
The content of VJOncology is intended for healthcare professionals